1. Home /
    2. Altai Protocol Library /
  2. New Indication: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

New Indication: Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Study:
  • Open-label, phase 3 trial
  • Stage IB to IIIA resectable NSCLC
  • Three cycles neoadjuvant treatment
  • Nivolumab plus platinum-based chemotherapy (N:176) or platinum-based chemotherapy (N:176)
Efficacy:
  • mEFS: 31.6 m vs 20.8 m (HR:0.63; 97.38% CI, 0.43 to 0.91; P=0.005)
  • Pathological CR 24.0% vs 2.2% (OR:13.94; 99% CI, 3.49 to 55.75; P<0.001)
  • mOS:NR vs NR (HR: 0.57; 99.67% CI, 0.30 to 1.07; P=0.008)
Safety:
  • Grade >= 3 AEs: 33.5% vs 36.9%
  • Grade >=3 AEs neutropenia:8.5% vs 11.9%
  • Discontinuation of treatment 10.2% vs 9.7%

N Engl J Med 2022 May 26;386(21):1973-1985.

Forde, Patrick M et al. “Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.”

https://doi.org/10.1056/nejmoa2202170

Reviewed by Hasan Çağrı Yıldırım, MD on Jul 05, 2022

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More